Today: 7 February 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

American Airlines Stock (AAL) News Today: S&P EETC Upgrade, UBS “Buy” Call, and Holiday Travel Catalyst in Focus (Dec. 16, 2025)

American Airlines Stock (AAL) News Today: S&P EETC Upgrade, UBS “Buy” Call, and Holiday Travel Catalyst in Focus (Dec. 16, 2025)

American Airlines Group Inc. (NASDAQ: AAL) is back on investors’ radar on Tuesday, December 16, 2025, as the carrier heads into a high-stakes holiday travel stretch while fresh updates from credit markets and Wall Street analysts reshape the near-term narrative. After closing Monday, Dec. 15 at $15.33 (+2.47%)—with a session range of roughly $14.86 to $15.35 on heavy volume—AAL entered Tuesday’s session with momentum and plenty of headline gravity. Investing.com Below is a full, up-to-date roundup of the current news, forecasts, and market analysis shaping American Airlines stock as of 16.12.2025—and what investors are watching next. AAL stock snapshot: what
16 December 2025
·
Tesla Stock (TSLA) News Today: Robotaxi Tests Fuel Rally, But Wall Street Forecasts Split Wide on Dec. 16, 2025

Tesla Stock (TSLA) News Today: Robotaxi Tests Fuel Rally, But Wall Street Forecasts Split Wide on Dec. 16, 2025

Tesla, Inc. (NASDAQ: TSLA) is trading around $475 on December 16, 2025, keeping the stock near the upper end of its recent range after Monday’s sharp move. As of 11:41 UTC, TSLA was $475.31, up about 3.5% versus the prior close. Investing.com What’s driving the attention isn’t a new vehicle launch or a quarterly earnings surprise—it’s the same narrative that has increasingly dominated Tesla’s market value in 2025: autonomy. A fresh milestone in Tesla’s robotaxi testing has energized bulls, while skeptics point to valuation, regulatory scrutiny, and the simple fact that Tesla still makes most of its money the old-fashioned
16 December 2025
··
Uber Stock (UBER) Slides on FTC Uber One Lawsuit as Analysts Hold Bullish Targets — What to Know on Dec. 16, 2025

Uber Stock (UBER) Slides on FTC Uber One Lawsuit as Analysts Hold Bullish Targets — What to Know on Dec. 16, 2025

Uber Technologies, Inc. (NYSE: UBER) stock traded lower on Tuesday, December 16, 2025, as investors digested an escalated regulatory challenge tied to the company’s Uber One subscription program—while Wall Street’s broader outlook on the rideshare and delivery leader stayed notably constructive. As of 11:22 UTC on Dec. 16, Uber shares were at $81.86, down about 3.84% from the prior close. The day’s move highlights a familiar pattern for Uber stock: near-term volatility driven by legal and regulatory headlines, set against a longer-running debate about whether Uber’s platform strategy—spanning Mobility, Delivery, and an expanding set of partnerships—can compound profitably into 2026
16 December 2025
·
Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight on December 16, 2025, with the stock trading around $54.29, up roughly 3.6% on the session as optimism builds around Wall Street upgrades, a newly announced dividend increase, and a steady drumbeat of pipeline and regulatory updates heading into 2026. Smartkarma While BMY has spent much of the past year wrestling with familiar big-pharma headwinds—generic erosion in legacy products and a looming “patent cliff” narrative—the last several weeks have looked more like a sentiment reset than a victory lap. One analysis notes a ~16% move over the last 30 days
16 December 2025
···
Terns Pharmaceuticals (TERN) Stock Today: Latest News, Analyst Forecasts, and What to Watch (December 16, 2025)

Terns Pharmaceuticals (TERN) Stock Today: Latest News, Analyst Forecasts, and What to Watch (December 16, 2025)

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) is still living inside one of the more dramatic biotech story arcs of 2025: eye-popping clinical data, followed immediately by a massive equity raise, followed by a flurry of analyst price-target resets. As of Tuesday, December 16, 2025, TERN shares were trading around $44. That price level matters because it sits right on top of the two big forces investors have been digesting all month: Below is a complete, publication-ready roundup of the current news, forecasts, and market analysis shaping Terns Pharmaceuticals stock as of 16.12.2025, plus the catalysts that could drive the next move.
16 December 2025
··
Venus Concept Inc. (NASDAQ: VERO) Stock: Latest News, Catalysts, and Forecasts as of December 16, 2025

Venus Concept Inc. (NASDAQ: VERO) Stock: Latest News, Catalysts, and Forecasts as of December 16, 2025

Venus Concept Inc. stock (NASDAQ: VERO) is back on traders’ radar in mid-December 2025—less because it’s a calm, steadily compounding story (it isn’t), and more because the company has stacked multiple high-impact catalysts and balance-sheet developments into a tight window. As of the Dec. 15 close, VERO finished around $1.67, down roughly 10.7% on the day, and early Dec. 16 pre-market quotes indicated a sharp rebound attempt near $2.16—a reminder that this remains a thinly traded micro-cap where price can gap hard in either direction. StockAnalysis Below is a full, publication-ready breakdown of the latest company news, what recent filings
16 December 2025
·
Inspire Veterinary Partners (IVP) Stock News Today: Nasdaq Delisting Risk, Dilution Signals, and 2026 Catalysts (Dec. 16, 2025)

Inspire Veterinary Partners (IVP) Stock News Today: Nasdaq Delisting Risk, Dilution Signals, and 2026 Catalysts (Dec. 16, 2025)

December 16, 2025 — Inspire Veterinary Partners, Inc. (NASDAQ: IVP) is once again on traders’ radar, but not for the comforting reasons investors typically like in a healthcare-services name. The stock is trading around $0.05 per share in early Tuesday action, after a stretch of extreme volatility driven by Nasdaq listing risk, capital-structure changes, and a growing conversation around potential dilution. Investing.com Below is a complete, up-to-date rundown of the latest IVP stock news, filings, forecasts, and analysis as of December 16, 2025, plus what to watch next. IVP stock price action on December 16, 2025: microcap volatility on full
16 December 2025
·
Pfizer Stock (PFE) Today, Dec. 16, 2025: 2026 Guidance Call Looms as Analysts Weigh Dividend, Deal Flow, and Policy Risks

Pfizer Stock (PFE) Today, Dec. 16, 2025: 2026 Guidance Call Looms as Analysts Weigh Dividend, Deal Flow, and Policy Risks

Pfizer Inc. (NYSE: PFE) heads into Tuesday, December 16, 2025 with a familiar “big pharma” cocktail of catalysts: an imminent guidance event, a high dividend yield, fresh dealmaking in hot therapeutic areas (immunology and obesity), and a regulatory backdrop that can flip sentiment faster than a lab centrifuge. Shares closed Monday at $26.43, up 2.24%, extending a four-session winning streak, according to MarketWatch. MarketWatch On the data side, Pfizer’s own calendar is the center of gravity: the company is scheduled to host an 8:00 a.m. EST analyst call today to provide full-year 2026 financial guidance. Pfizer+1 Below is what’s driving
16 December 2025
···
Nektar Therapeutics Stock (NKTR) Surges Into a Major Catalyst: What to Know Ahead of Today’s REZOLVE-AA Data

Nektar Therapeutics Stock (NKTR) Surges Into a Major Catalyst: What to Know Ahead of Today’s REZOLVE-AA Data

Nektar Therapeutics (NASDAQ: NKTR) is in classic “biotech catalyst mode” on December 16, 2025—the kind of day when a single dataset can rewrite a stock chart in minutes. Shares climbed in pre-market and overnight trading as investors positioned for topline results from the 36-week induction period of Nektar’s Phase 2b REZOLVE-AA study in severe-to-very-severe alopecia areata, featuring its lead investigational candidate rezpegaldesleukin (REZPEG / NKTR-358). The company scheduled an investor call and webcast for 8:00 a.m. ET, and said the topline results would be released in a morning press release before the webcast. PR Newswire+1 By the numbers, NKTR closed
16 December 2025
··
SAVE Plan Shutdown: Student Loan Payments Could Restart for Millions—What Borrowers Need to Know (Dec. 16, 2025)

SAVE Plan Shutdown: Student Loan Payments Could Restart for Millions—What Borrowers Need to Know (Dec. 16, 2025)

Dec. 16, 2025 — Millions of Americans enrolled in the Biden-era Saving on a Valuable Education (SAVE) student loan repayment plan are facing a major—and fast-moving—shift that could end a long stretch of ultra-low or even $0 monthly bills. The U.S. Department of Education says it has reached a proposed settlement with Missouri that would end the SAVE plan, halt new enrollments, deny pending applications, and move current SAVE borrowers into other repayment options—pending court approval. U.S. Department of Education+1 For borrowers, the immediate reality is a mix of urgency and uncertainty: the department says SAVE enrollees will have a
16 December 2025
uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

Dec. 16, 2025 — uniQure N.V. (NASDAQ: QURE) is back in the spotlight Tuesday after a notable extended-hours rebound. The gene therapy developer’s shares were highlighted among top pre-market gainers, rising about 15% to roughly $23.50 in early trading, following a strong after-hours move the prior session. StockAnalysis+1 The snapback comes at a time when the fundamental narrative around uniQure remains dominated by one big question: how (and when) the U.S. FDA will allow AMT-130—uniQure’s Huntington’s disease gene therapy—to move toward a Biologics License Application (BLA) after the agency signaled the current evidence package is not sufficient as “primary” support
16 December 2025
··
Procter & Gamble Stock (PG) News Today: Price Rally Extends, Leadership Shifts, Dividend Outlook and Analyst Forecasts (December 16, 2025)

Procter & Gamble Stock (PG) News Today: Price Rally Extends, Leadership Shifts, Dividend Outlook and Analyst Forecasts (December 16, 2025)

December 16, 2025 — The Procter & Gamble Company (NYSE: PG) is back in the market’s good graces after a choppy year for consumer staples. PG shares finished the latest session up 1.60% at $145.13, extending the stock’s winning streak to five straight days even as the broader market slipped. marketwatch.com That near-term momentum is colliding with a very “P&G” mix of catalysts: executive turnover, an approaching CEO handoff, and investor focus on dividends and pricing power. Here’s what’s driving Procter & Gamble stock today, what Wall Street is forecasting, and what to watch next as 2026 begins to loom
16 December 2025
··
Affirm Holdings (AFRM) Stock News Today: CFO Fireside Chat, Analyst Targets, and BNPL Scrutiny in Focus (Dec. 16, 2025)

Affirm Holdings (AFRM) Stock News Today: CFO Fireside Chat, Analyst Targets, and BNPL Scrutiny in Focus (Dec. 16, 2025)

December 16, 2025 — Affirm Holdings, Inc. (NASDAQ: AFRM) heads into today with investors watching two forces that can move buy-now-pay-later (BNPL) stocks fast: company messaging and policy risk. Shares closed Monday, Dec. 15 at $65.66, down 2.36% on the day, setting the stage for today’s investor-focused event featuring the company’s CFO. StockAnalysis That event—an interactive CFO fireside chat scheduled for 9:00 a.m. Pacific—is the most immediate near-term catalyst for AFRM on the calendar, arriving after a newsy December that’s mixed product/merchant momentum with rising attention on BNPL oversight. Business Wire What’s happening today: Affirm’s CFO fireside chat (and why
16 December 2025
·
Singapore Bank Stocks Hit Record Highs on Dec 16, 2025: DBS and OCBC Surge, UOB Lags as Investors Eye Dividends and 2026 Momentum

Singapore Bank Stocks Hit Record Highs on Dec 16, 2025: DBS and OCBC Surge, UOB Lags as Investors Eye Dividends and 2026 Momentum

SINGAPORE — December 16, 2025. Singapore’s bank-heavy equity market delivered a fresh headline on Tuesday: DBS and OCBC both notched new all-time highs, reinforcing a late‑2025 narrative that the “big three” banks remain core holdings for income-focused investors—just as the debate shifts to whether the rally can hold into 2026. The Business Times But the story is bigger than a single day’s price action. What’s driving the sector now is a powerful mix of capital return expectations, structural wealth inflows, a loan-growth rebound, and a new China-linked payments milestone for DBS—while UOB’s asset-quality and provisioning profile continues to keep it
16 December 2025
···
Tesla Stock (TSLA) Surges on Driverless Robotaxi Tests: Latest News, Analyst Forecasts, and Key Risks for December 16, 2025

Tesla Stock (TSLA) Surges on Driverless Robotaxi Tests: Latest News, Analyst Forecasts, and Key Risks for December 16, 2025

Tesla, Inc. (NASDAQ: TSLA) is back at the center of the market conversation on December 16, 2025, after a fresh burst of optimism around the company’s autonomous-driving ambitions pushed shares higher. Tesla stock was trading around $475, up roughly 3.5%, and sitting near the top of its 52‑week range. Investing.com The catalyst isn’t a new Model Y refresh or a surprise earnings beat. It’s a classic Tesla storyline: autonomy progress + big valuation arguments + very loud disagreement among analysts about what it all should be worth. Below is what’s driving TSLA today, what major forecasts are saying, and what
16 December 2025
···
Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)

Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)

Immunome, Inc. (NASDAQ: IMNM) is in the spotlight on December 16, 2025, after the company reported positive topline Phase 3 results for its lead desmoid tumor program and then moved to raise significant new capital—two catalysts that can push a biotech stock in opposite directions at the same time. On the one hand: a clear late-stage efficacy win that supports an FDA filing. On the other: a proposed $400 million common stock offering that introduces near-term dilution risk. Reuters+2Immunome Investors+2 Below is a comprehensive, news-driven look at what happened, what analysts are forecasting, and what matters next for IMNM stock
16 December 2025
·
Zillow Group Stock (ZG) Drops After Google Tests Home Listings in Search: Analyst Targets, Forecasts and Key Risks (Dec. 16, 2025)

Zillow Group Stock (ZG) Drops After Google Tests Home Listings in Search: Analyst Targets, Forecasts and Key Risks (Dec. 16, 2025)

Zillow Group, Inc. shares are under pressure on Tuesday, December 16, 2025, as investors react to a sudden, very modern fear: what happens if Google decides it wants to “be the front door” to home search, not just the street sign pointing to it? In the latest trading data available Tuesday, Zillow’s Class A shares (NASDAQ: ZG) were down roughly 8%, and the company’s Class C shares (NASDAQ: Z) were down a similar amount, extending a sharp selloff that began Monday after reports that Google is testing home listing features directly inside Search results. Investopedia The market’s message is clear:
16 December 2025
·····
UK Crypto Regulation 2025: FCA Launches Sweeping Rules Consultation for Exchanges, Staking and Lending Ahead of 2027 Rollout

UK Crypto Regulation 2025: FCA Launches Sweeping Rules Consultation for Exchanges, Staking and Lending Ahead of 2027 Rollout

LONDON — On December 16, 2025, the UK’s Financial Conduct Authority (FCA) published the most comprehensive set of proposals yet for how Britain intends to regulate crypto markets — covering everything from token listings and market abuse to staking, crypto lending and decentralised finance (DeFi). The consultation marks a major step toward a full UK “crypto regime” that the government says will begin taking effect from October 2027. FCA+2Reuters+2 The FCA is positioning its approach as a familiar one for the City: bring crypto closer to traditional financial regulation by focusing on clear consumer information, market integrity and financial safeguards
16 December 2025
·
XRP Price Today Breaks Key Support Below $2 as Crypto Sell-Off Deepens — What’s Driving the Drop on Dec. 16, 2025

XRP Price Today Breaks Key Support Below $2 as Crypto Sell-Off Deepens — What’s Driving the Drop on Dec. 16, 2025

December 16, 2025 — XRP (the token closely associated with Ripple’s ecosystem) slid further Tuesday, extending a multi-week soft patch and turning a familiar psychological line in the sand — $2 — into a fresh point of market anxiety. In early trading, XRP fell into the $1.80s, with multiple reports placing the move around $1.87–$1.88, as the broader crypto market flipped risk-off and leveraged positions were forced out. MEXC+2Stocktwits+2 The headlines may look like “just another down day” in a volatile asset class. But beneath the surface, Tuesday’s slide has a clear structure: a technical break of a widely watched
16 December 2025
·
India Markets Today: Rupee Breaks 91 per Dollar, Stocks Slip as Trade-Talk Uncertainty Collides With a Deal-and-Realty Wave

India Markets Today: Rupee Breaks 91 per Dollar, Stocks Slip as Trade-Talk Uncertainty Collides With a Deal-and-Realty Wave

On December 16, 2025, India’s financial markets were forced to juggle two powerful (and competing) narratives: The result: a classic “macro vs micro” day—macro pressure from FX, flows, and trade policy uncertainty… meeting micro momentum from corporate actions, listings, and sector upcycles (including real estate). Rupee crosses 91: what happened, and why it mattered immediately The rupee breached ₹91/$ on Tuesday and extended its run of record lows, with market participants pointing to heavier hedging demand, portfolio outflows, and continued uncertainty around U.S.–India trade negotiations. Reuters By the close, Indian market updates widely tracked the rupee finishing around ₹91.03 per
16 December 2025
1 … 392 393 394 395 396 … 535

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Go toTop